{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:54:09Z","timestamp":1792173249742,"version":"4.4.0"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2020LZL018"],"award-info":[{"award-number":["ZR2020LZL018"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303749"],"award-info":[{"award-number":["82303749"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH292"],"award-info":[{"award-number":["ZR2023QH292"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The FLAURA2 and MARIPOSA trials established survival benefits of osimertinib plus chemotherapy and amivantamab plus lazertinib, respectively, over osimertinib monotherapy in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitizing mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the cost-effectiveness of osimertinib plus chemotherapy versus amivantamab plus lazertinib from the US and Chinese healthcare perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>An economic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A partitioned survival model with 28-day cycles was developed to simulate total costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) over a 10-year time horizon. Clinical efficacy and safety inputs were derived from FLAURA2 and MARIPOSA. Costs and utilities were sourced from public bid-winning databases, local charges, and published literature. A scenario analysis incorporated the amivantamab patient assistance program (PAP) in China. One-way and probabilistic sensitivity analyses (OWSA, PSA) assessed model uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Compared with osimertinib monotherapy, the ICERs for osimertinib plus chemotherapy were $551,944\/QALY (US) and $37,965\/QALY (China). For amivantamab plus lazertinib, ICERs were $2,186,499\/QALY (US) and $291,478\/QALY (China). OWSA identified drug prices and utility values as key drivers. PSA indicated that in the US, osimertinib was cost-effective in 100% of simulations at a $150,000\/QALY threshold. In China, at a $41,983.66\/QALY threshold, osimertinib plus chemotherapy had a 74.10% probability of being cost-effective. The PAP scenario did not alter the conclusion for amivantamab plus lazertinib in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on indirect comparisons, osimertinib monotherapy is the cost-effective option for advanced EGFR-mutant NSCLC in the US. In China, osimertinib plus chemotherapy represents the optimal regimen given current pricing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261465356","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:30:39Z","timestamp":1784957439000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China"],"prefix":"10.1177","volume":"18","author":[{"given":"Yihong","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1445-4057","authenticated-orcid":false,"given":"Shixian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China"},{"name":"NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China"},{"name":"Center for Health Management and Policy Research, Shandong University (Shandong Provincial Key New Think Tank), Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Song","sequence":"additional","affiliation":[{"name":"Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfei","family":"Liu","sequence":"additional","affiliation":[{"name":"Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-4424","authenticated-orcid":false,"given":"Wen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-6228","authenticated-orcid":false,"given":"Jisheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00757-8"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji055"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000033"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7576"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv319"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3854"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510308"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01679-1"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00515"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503001"},{"key":"e_1_3_4_17_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer","author":"National Comprehensive Cancer Network","year":"2025","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2025."},{"key":"e_1_3_4_18_2","volume-title":"Guidelines of Chinese society of clinical oncology (CSCO) 2025","author":"Chinese Society of Clinical Oncology","year":"2025","unstructured":"Chinese Society of Clinical Oncology. Guidelines of Chinese society of clinical oncology (CSCO) 2025. Beijing: People\u2019s Medical Publishing House (PMPH), 2025."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70083"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108533"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.01.011"},{"key":"e_1_3_4_22_2","volume-title":"China guidelines for pharmacoeconomic evaluation","author":"Liu G","year":"2025","unstructured":"Liu G, Wu J. China guidelines for pharmacoeconomic evaluation. Beijing: China Market Press, 2025."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2018.1447828"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0064-3"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.012"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-354"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.08.009"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11992-6"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.117"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1594786"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12477"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01038-z"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-025-00613-z"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318299243b"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0069"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0419-2"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251366946"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00329-8"},{"key":"e_1_3_4_40_2","article-title":"Promoting access to innovative anticancer medicines: a review of drug price and national reimbursement negotiation in China","volume":"60","author":"Mingge X","year":"2023","unstructured":"Mingge X, Jingyu W, Qi L, et al. Promoting access to innovative anticancer medicines: a review of drug price and national reimbursement negotiation in China. Inquiry 2023; 60: 469580231170729.","journal-title":"Inquiry"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.11016"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.920479"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1527614"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261465356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261465356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261465356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T03:46:29Z","timestamp":1785123989000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261465356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"alternative-id":["10.1177\/17588359261465356"],"URL":"https:\/\/doi.org\/10.1177\/17588359261465356","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17588359261465356"}}